Adverse effects of anticancer agents that target the VEGF pathway

@article{Chen2009AdverseEO,
  title={Adverse effects of anticancer agents that target the VEGF pathway},
  author={Helen X. Chen and Jessica N. Cleck},
  journal={Nature Reviews Clinical Oncology},
  year={2009},
  volume={6},
  pages={465-477}
}
Antiangiogenesis agents that target the VEGF/VEGF receptor pathway have become an important part of standard therapy in multiple cancer indications. With expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions and homeostasis in the cardiovascular and renal systems, as well as wound healing and tissue repair. Although most adverse effects of VEGF inhibitors are… 

Pathways mediating VEGF-independent tumor angiogenesis.

  • N. Ferrara
  • Biology, Medicine
    Cytokine & growth factor reviews
  • 2010

VEGF Inhibition, Hypertension, and Renal Toxicity

TLDR
These therapies, as a general class of anti-angiogenic medications, have been shown to have common adverse vascular effects attributable directly or indirectly to their anti-VEGF effects, including hypertension, renal vascular injury, often manifested by proteinuria and thrombotic microangiopathy, and congestive heart failure.

Dopamine is a safe antiangiogenic drug which can also prevent 5‐fluorouracil induced neutropenia

TLDR
The results indicate that DA may be safely used as an antiangiogenic drug for the treatment of malignant tumors and prevented 5‐fluorouracil induced neutropenia in HT29 colon cancer bearing mice.

The VEGF family in cancer and antibody-based strategies for their inhibition

TLDR
This review will focus on VEGF pathway targeting antibodies that are currently being evaluated in pre-clinical and clinical studies.

Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

TLDR
The development of rash with tyrosine kinase inhibitors or monoclonal antibodies targeting the epidermal growth factor receptor is associated with superior outcomes in lung, head and neck, colorectal, and pancreatic cancer studies and may be a marker of effective target inhibition.

Chapter 19 Anti-VEGF Therapy in Cancer : A Double-Edged Sword

TLDR
Tumor therapies targeting VEGF along with their side effects are presented and, finally, new directions in anti-VEGF therapy are considered along with the challenges.

Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy.

TLDR
A new combination strategy is introduced that links direct antiangiogenic protein and enzyme prodrug system with dual-targeting antiangIogenic and antiproliferative therapeutic effect in tumor microenvironment and has the potential to overcome clinical hindrances.

The role of angiogenesis inhibitors in the management of melanoma.

TLDR
An overview of the importance of angiogenesis in melanoma is presented and draws attention to some of the key molecules that are currently being targeted rationally within clinical studies, including anti-angiogenic and anti-vascular agents and their mechanisms of action.
...

References

SHOWING 1-10 OF 107 REFERENCES

VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function.

TLDR
Inhibition of VEGFR2 significantly increases systolic and diastolic blood pressure and reduces the number of microvessels in patients with advanced solid tumours treated with BAY 57-9352, an oral VEGF receptor 2 (VEGFR2) inhibitor.

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

TLDR
There are three US Food and Drug Administration–approved angiogenesis inhibitors for the treatment of cancer that specifically target vascular endothelial growth factor (VEGF) signaling and a plethora of new small-molecule tyrosine kinase inhibitors in preclinical development and early-phase clinical trials that target VEGFR with varying degrees of specificity.

Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.

  • T. Choueiri
  • Medicine, Chemistry
    Current opinion in investigational drugs
  • 2008
TLDR
Although frequent side effects have included fatigue, hypertension, diarrhea, hand-foot syndrome and proteinuria, axitinib was well tolerated overall.

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

TLDR
Although axitinib inhibits platelet-derived growth factor receptors and KIT with nanomolar in vitro potencies, based on pharmacokinetic/pharmacodynamic analysis, axitine acts primarily as a VEGFR tyrosine kinase inhibitor at the current clinical exposure.

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.

  • S. WedamJ. Low S. Swain
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
Bvacizumab has inhibitory effects on VEGF receptor activation and vascular permeability, and induces apoptosis in tumor cells, and persists with the addition of chemotherapy.

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

  • N. AzadE. Posadas E. Kohn
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
Combination therapy with sorafenib and bevacizumab has promising clinical activity, especially in patients with ovarian cancer, but the rapidity and frequency of sorAFenib dose reductions indicates that sorafanib at 200 mg twice daily with bevacsumab 5 mg/kg every 2 weeks may not be tolerable long term, and alternate sorafinib dosing schedules should be explored.

Bevacizumab in the treatment of ovarian cancer

TLDR
Management issues related to the treatment of ovarian cancer are discussed, with a focus on the utilization of bevacizumab, summarizing applicable clinical trials, its potential benefits, and reported adverse events.

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

  • N. Ferrara
  • Biology, Medicine
    Seminars in oncology
  • 2002

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors

TLDR
Biochemical findings of thyroid dysfunction in a patient treated with sunitinib for recurrence of gastrointestinal stromal tumor and patient-reported fatigue noted during clinical trials led to the monitoring of serum thyroid-stimulating hormone (TSH) concentrations to rule out primary hypothyroidism.
...